Carnosine

Carnosine (beta-alanyl-L-histidine) is a naturally occurring dipeptide composed of the amino acids beta-alanine and histidine. It is found in high concentrations in skeletal muscle, cardiac muscle, and brain tissue, with particularly high levels in type II fast-twitch muscle fibers. First discovered in 1900 by the Russian chemist Vladimir Gulevich, carnosine has since been the subject of extensive research into its multiple biological activities.

The peptide functions as a pluripotent biological agent with several well-documented mechanisms of action. As an antioxidant, carnosine directly scavenges reactive oxygen species (ROS) and reactive nitrogen species. It also acts as a metal ion chelator, binding copper and zinc ions that can catalyze oxidative reactions. Perhaps most distinctively, carnosine is a potent anti-glycation agent, capable of reacting with and neutralizing advanced glycation end-products (AGEs) — damaging compounds formed when sugars react with proteins or lipids that accumulate with aging and in metabolic diseases.

Research has explored carnosine's potential in numerous contexts including cognitive function, exercise performance, cardiovascular health, and metabolic disorders. Studies in animal models have shown carnosine supplementation can extend lifespan, reduce oxidative stress markers, and improve cognitive function in aging animals. In human studies, carnosine supplementation has shown potential benefits in improving glycemic control in prediabetic and diabetic individuals, and in supporting cognitive function in elderly populations.

The bioavailability of oral carnosine is limited by the enzyme carnosinase, which rapidly degrades carnosine in human blood plasma. This has led to interest in carnosine analogs and delivery strategies that resist enzymatic degradation. Despite this limitation, oral supplementation has shown measurable effects in clinical studies, suggesting sufficient tissue uptake occurs.